Skip to main navigation

Codiak Biosciences

Investor Relations - Top Nav

Our Science
Our Science

Through our proprietary engEx™ Platform, we are harnessing the power of nature’s intercellular communication system to engineer a new class of medicines, exosome therapeutics.
Manufacturing
Pipeline & Programs
Pipeline & Programs

We are utilizing our engEx™ Platform to build a broad pipeline of therapeutic candidates that we believe can have a transformative impact on the treatment of a broad spectrum of diseases, with an initial focus on oncology and neurology.
About Us
About Us

At Codiak, we are working to create a major shift in the development of tomorrow’s medicines through scientific ambition, remarkable ingenuity and determined passion for improving patients’ lives.
Careers
Investors & Media
Investors & Media

Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines.

Press Releases

Year

November 28, 2022

Codiak BioSciences to Participate 5th Annual Evercore ISI HealthCONx Conference

Additional Formats

PDF Version

November 10, 2022

Codiak Presents Preclinical Data on exoASO™-STAT6 and exoASO™-C/EBPβ Programs at the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting

Additional Formats

PDF Version

November 3, 2022

Codiak BioSciences Reports Third Quarter 2022 Financial Results and Operational Progress

Additional Formats

PDF Version

October 12, 2022

Codiak Presents Preclinical Data Demonstrating its Pan Beta-Coronavirus Vaccine Elicits Broad Protective Immunity Against Known Variants of SARS-CoV-2 and Related Sarbecoviruses

Additional Formats

PDF Version

October 5, 2022

Codiak to Present New Preclinical Data Demonstrating Potent Monotherapy Activity of Two Engineered Exosome Intravenous Candidates Targeting Macrophages

Additional Formats

PDF Version

September 12, 2022

Codiak Announces Pricing of $20 Million Public Offering of Common Stock and Warrants

Additional Formats

PDF Version

September 12, 2022

Codiak Announces Proposed Public Offering of Common Stock and Warrants

Additional Formats

PDF Version

August 30, 2022

Codiak BioSciences Announces Program Reprioritization and Corporate Restructuring

Additional Formats

PDF Version

August 4, 2022

Codiak BioSciences Reports Second Quarter 2022 Financial Results and Operational Progress

Additional Formats

PDF Version

August 3, 2022

Codiak BioSciences to Participate in Upcoming BTIG and Wedbush PacGrow Investor Conferences

Additional Formats

PDF Version

Pagination

Current page 1
Page 2
Page 3
Next page
Last page

Displaying 1 - 10 of 22

Join our team of experts working at the forefront of advancing engineered exosomes. Explore Careers

© 2022 All Rights Reserved.

Footer Links

Contact
Privacy Policy
Terms of Use

LinkedIn Twitter